GlassScriptPhysician profile
Renee Bujol
NPI 1548751142
$4,271.30
in general payments reported to CMS, 2019-2025
32 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $1,076 · 2023: $540 · 2024: $1,063 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.83 | 2021-2025 | |
| Novo Nordisk INC | $612.18 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $462.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $303.03 | 2021-2025 | |
| Glaxosmithkline, LLC. | $279.35 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $248.38 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $244.99 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $161.85 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.11 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $94.54 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $91.99 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $83.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $83.31 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.05 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.47 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $52.48 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $50.68 | 2021 | |
| Lundbeck LLC | $48.48 | 2024-2025 | Rexulti |
| Acerus Pharmaceuticals Corporation | $44.21 | 2022 | |
| Xeris Pharmaceuticals, INC. | $40.53 | 2022-2024 | Gvoke Hypopen |
| Amgen INC. | $38.08 | 2022-2024 | Prolia, Evenity, Repatha |
| Corium, LLC | $31.45 | 2024-2025 | Azstarys |
| Exact Sciences Corporation | $28.70 | 2024-2025 | Cologuard Collection Kit |
| Merz North America, INC. | $25.49 | 2023 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $25.23 | 2022 | |
| Dexcom, INC. | $24.77 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $20.71 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $19.19 | 2025 | |
| Currax Pharmaceuticals LLC | $17.89 | 2025 | Contrave |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.61 | 2024 | Caplyta |
| Dynavax Technologies Corporation | $16.66 | 2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Bujol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.